Tuvatexib is a potent, selective small molecule modulator of Hexokinase 2 (HK2) interaction with the mitochondria, selectively dissociates HK2 from VDAC1 in vitro with IC50 of 92 nM; does not affect the VDAC1/HK1 complex; dose-dependent reduces mitochondrial-bound HK2 levels in human skin SCC A431 cells with IC50 of 0.8 uM, reduces glycolysis and triggers apoptosis in cancer cells, without affecting hexokinase 1-expressing normal cells; displays anti-cancer activity in UVB-damaged skin model in SKH-1 mice. References: Krasnov GS, Dmitriev AA, Lakunina VA, Kirpiy AA, Kudryavtseva AV. Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert Opin Ther Targets. 2013 Oct;17(10):1221-33. doi: 10.1517/14728222.2013.833607. Epub 2013 Aug 28. Review. PubMed PMID: 23984984.

纯度：≥98%

CAS：2055404-90-3